Posttransplant Epstein-Barr virus related lymphoproliferative disorder with a primary cutaneous presentation.
Posttransplant lymphoproliferative disorder is a rare and often difficult diagnosis in patients with only cutaneous symptoms. A stepwise approach to diagnosis and classification can lead to successful treatment. We report a case of an EBV-associated posttransplant lymphoproliferative disorder (PTLD) occurring on the face with a primary cutaneous presentation. The appropriate diagnosis was made only after multiple biopsies and special stains. There was near complete resolution with decreased levels of iatrogenic immunosuppression. The diagnosis of Posttransplant lymphoproliferative disorder can be difficult to establish. A proper workup will aid in making an accelerated diagnosis and choosing appropriate treatment options.
Snavely
Nicholas R
NR
Michael E. DeBakey Veterans Administration Medical Center, Baylor College of Medicine, Houston, Texas, USA.
Sonabend
Michael
M
Rosen
Ted
T
D004305:Dose-Response Relationship, Drug; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D005145:Face; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016040:Lung Transplantation; D008232:Lymphoproliferative Disorders / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives; D011241:Prednisone / Q000009:adverse effects; D011658:Pulmonary Fibrosis / Q000601:surgery; D020123:Sirolimus / Q000009:adverse effects; D012871:Skin Diseases / Q000209:etiology*
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D011241:Prednisone; D020123:Sirolimus